Suggested remit: To appraise the clinical and cost effectiveness of Depemokimab within its marketing authorisation for treating rhinosinusitis.

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Depemokimab, our new long-acting anti-IL-5 medicine has now been filed in all major markets for dual approval in severe asthma and chronic rhinosinusitis with nasal polyps. Depemokimab has the ...

Beyond COPD, regulatory submissions are underway in chronic rhinosinusitis with nasal polyps, supported by positive ... very, very nice job of making sure that that we have a path to helping ...

NICE based its decision in part on results ... people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a condition that impacts nearly 30 million people in China.

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...